A citation-based method for searching scientific literature

Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin M Valdes, Elizabeth H Z Thompson, Hervé Bachelez. Lancet 2018
Times Cited: 278



Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, Mamitaro Ohtsuki, Kristian Reich, David Amato, Susan G Ball, Daniel K Braun, Gregory S Cameron, Janelle Erickson, Robert J Konrad, Talia M Muram, Brian J Nickoloff, Olawale O Osuntokun, Roberta J Secrest, Fangyi Zhao, Lotus Mallbris, Craig L Leonardi. N Engl J Med 2016
Times Cited: 473




List of shared articles



Times cited

An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan.
Hidehisa Saeki, Kanako Ishii, Avani Joshi, Arielle G Bensimon, Hongbo Yang, Isao Kawaguchi. J Dermatolog Treat 2022
3

Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.
Najeeda Yasmeen, Laura M Sawyer, Kinga Malottki, Lars-Åke Levin, Eydna Didriksen Apol, Gregor B Jemec. J Dermatolog Treat 2022
17

Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12.
Alice B Gottlieb, Daniel Saure, Stefan Wilhelm, Martin Dossenbach, Christopher Schuster, Saxon D Smith, Yuval Ramot, Diamant Thaçi. J Dermatolog Treat 2022
5

Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: post-hoc analysis from the phase III, double-blind, placebo- and active-comparator-controlled VOYAGE 1/2 trials.
Sang Woong Youn, Dae Young Yu, Tae Yoon Kim, Byung Soo Kim, Seung Chul Lee, Jeung Hoon Lee, Yong-Beom Choe, Joo-Heung Lee, Jee-Ho Choi, Joo Young Roh,[...]. J Dermatolog Treat 2022
1

PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines.
Isabel Belinchón Romero, Esteban Dauden, Carlos Ferrándiz Foraster, Álvaro González-Cantero, Jose Manuel Carrascosa Carrillo. J Dermatolog Treat 2022
3

Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial.
D Thaçi, K Eyerich, A Pinter, M Sebastian, K Unnebrink, S Rubant, D A Williams, P Weisenseel. Br J Dermatol 2022
4

Saudi consensus statement on biologic treatment of chronic plaque psoriasis (2020).
Mohammad Ibrahim Ahmad Fatani, Issam Ribhi Ahmad Hamadah, Mohammed Abdulaziz Alajlan, Yousef Binamer, Aymen Hamed Salem Alharbi, Amaal Farhan Salman Alruwaili, Maha Abdulrahman Abdulateef Aldayel, Khalidah Ahmed Owdetallah Alenzi, Sultan Mohammed Mubarki, Amr Mohammad Khardaly,[...]. J Dermatolog Treat 2022
0


Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
M Gooderham, A Pinter, L K Ferris, R B Warren, T Zhan, J Zeng, A M Soliman, C Kaufmann, B Kaplan, H Photowala,[...]. J Eur Acad Dermatol Venereol 2022
1

Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.
Andrew Blauvelt, Melinda Gooderham, Christopher E M Griffiths, April W Armstrong, Baojin Zhu, Russel Burge, Gaia Gallo, Jiaying Guo, Alyssa Garrelts, Mark Lebwohl. Dermatol Ther (Heidelb) 2022
0

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis.
Craig L Leonardi, Kyoungah See, Russel Burge, Zhuoer Sun, Ying Zhang, Lotus Mallbris, Alyssa Garrelts, Richard B Warren. Adv Ther 2022
1

Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis.
Karine Rodríguez-Fernández, Víctor Mangas-Sanjuán, Matilde Merino-Sanjuán, Antonio Martorell-Calatayud, Almudena Mateu-Puchades, Mónica Climente-Martí, Elena Gras-Colomer. Pharmaceutics 2022
2



What Can IBD Specialists Learn from IL-23 Trials in Dermatology?
Mario Valenti, Alessandra Narcisi, Giulia Pavia, Luigi Gargiulo, Antonio Costanzo. J Crohns Colitis 2022
1

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Liz Doney, Corinna Dressler, Camille Hua, Carolyn Hughes, Luigi Naldi, Sivem Afach, Laurence Le Cleach. Cochrane Database Syst Rev 2022
0

Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
Andrew Blauvelt, Alexa B Kimball, Matthias Augustin, Yukari Okubo, Michael M Witte, Claudia Rodriguez Capriles, Angelina Sontag, Vipin Arora, Olawale Osuntokun, Bruce Strober. Br J Dermatol 2022
0

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.
April Armstrong, Kyle Fahrbach, Craig Leonardi, Matthias Augustin, Binod Neupane, Paulina Kazmierska, Marissa Betts, Andreas Freitag, Sandeep Kiri, Vanessa Taieb,[...]. Dermatol Ther (Heidelb) 2022
0

Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached?
Gangadhar Hari, Anoop Kishore, Sreedhara Ranganath Pai Karkala. Eur J Pharmacol 2022
0

The impact of the first COVID-19 wave on office-based dermatological care in Germany: a focus on diagnosis, therapy and prescription of biologics
Imke Nordhorn, Daniela Weiss, Thomas Werfel, Alexander Zink, Maximilian C Schielein, Stephan Traidl. Eur J Dermatol 2022
0

Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review.
Anjana Sevagamoorthy, Patrick Sockler, Christine Akoh, Junko Takeshita. J Dermatolog Treat 2022
0

Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry.
Abby S Van Voorhees, Marc A Mason, Leslie R Harrold, Ning Guo, Adriana Guana, Haijun Tian, Vivian Herrera, Bruce E Strober. J Dermatolog Treat 2021
4

Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry.
Abby S Van Voorhees, Marc A Mason, Leslie R Harrold, Ning Guo, Adriana Guana, Haijun Tian, Vivian Herrera, Bruce E Strober. J Dermatolog Treat 2021
0

Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis.
Nikolai Loft, Anne-Sofie Halling, Alexander Egeberg, Lone Skov. J Am Acad Dermatol 2021
9

Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.
Danni Ambikaibalan, Anna Sophie Quaade, Anne-Sofie Halling, Jacob P Thyssen, Alexander Egeberg. Dermatology 2021
1